Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02310321 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02310321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02310321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1/2
Overall status
Completed
Start date
February 26, 2015
Completion date
July 9, 2024
Enrollment
97 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, flt3-mutated acute myeloid leukemia